ORCL — Oracle Corporation

The mood is cautiously bullish: the stock has rebounded sharply from its summer low, analysts remain overwhelmingly Buy-rated, and Citi placed ORCL on a 90-day positive catalyst watch with a $330 target. The enthusiasm is tempered by persistent negative free cash flow, heavy debt, and high-profile short interest, but the near-term sentiment is clearly constructive.

Revenue growth has inflected upward over the past year. TTM revenue is about $67.4B, and the latest quarter (Q4 FY2026, ended May 2026) was $19.18B, up 20.6% YoY from $15.90B, with an 11.6% sequential jump from $17.19B. Two years ago quarterly revenue was only ~$12.45B, so the acceleration is structural, not a one-quarter blip. Operating margin is roughly stable: TTM operating margin is about 30.8%, flat versus a year earlier, though quarterly margins have ranged from 28.7% to 32.8%. EPS grew 22% YoY in the latest quarter to $1.45, but Q2 FY2026's $2.10 EPS is an outlier that flatters TTM comparisons. Overall take: accelerating revenue, stable margins, and earnings following revenue.

Cheap by its own history, though not without reason. As of 2026-08-27, the TTM P/E is 25.6x versus the 5-year average of 34.4x; P/S is 6.5x versus 7.0x; PEG is 0.77; and forward P/E on consensus FY2027 EPS of $8.06 is about 18.8x. The stock sits near the bottom of its 52-week range of $114.50-$345.72. The valuation discount is real but partly deserved because Oracle carries roughly $122B of long-term debt, a 3.67 debt-to-equity ratio, and negative trailing free cash flow. On a growth-adjusted basis, the stock looks attractive if the AI backlog converts.

At $151.92, the market is pricing in meaningful execution and cash-burn risk. A sub-19x forward multiple on >20% revenue growth and a $638B RPO backlog is a big de-rating versus the 34.4x 5-year average P/E. If Oracle converts even a reasonable portion of that backlog and FCF turns positive, both earnings and the multiple can re-rate higher. If the AI capacity bet fails or demand stalls, the low multiple is justified. This is a turn-and-re-rate story, not a momentum extrapolation.

Anchored to 2026-08-27: RSI was 57.23, neutral after being oversold earlier in the summer. Price was 4.1% above the 20-day SMA and 6.8% above the 50-day SMA, but 11.2% below the 200-day SMA, which is roughly $171. The rebound from $114 is intact in the short term, but the stock remains in a longer-term downtrend after peaking near $345. For entry timing, a clean reclaim of the 200-day on strong volume would be the most constructive signal; otherwise, a pullback toward the $135-$140 area would offer a better risk/reward entry.

• Higher interest rates raise the cost of servicing Oracle's ~$122B long-term debt and its large future data-center lease commitments.
• The AI infrastructure capex cycle is robust, but there is real debate about whether hyperscale buildout is overrunning actual workload demand.
• Oracle is both a partner and competitor to Microsoft, Amazon, and Alphabet in multi-cloud and infrastructure, keeping competitive tension high.
• Credit market access and rating agency scrutiny are material after the summer's concerns about Oracle's financing strategy.
• Sector rotation toward AI winners remains a tailwind, but high-capex, negative-FCF names are punished quickly if growth wobbles.

• Q1 FY2027 earnings expected around September 8-10, 2026: consensus EPS ~$1.67-$1.74 on revenue ~$19.13B; guidance and RPO conversion commentary will drive the next move.
• Investor/analyst day in late October 2026, which could provide a credible timeline for free-cash-flow inflection and operating-margin expansion.
• Further expansion of the $638B RPO backlog, especially new OCI/AI infrastructure contracts.
• Continued enterprise/public-sector wins such as the expanded VA healthcare agreement worth up to $17B.

• Negative free cash flow persists: the last four reported quarters totaled about -$23.7B, and FY2027 capex guidance of up to $55.7B-$95B keeps cash burn the #1 risk.
• Leverage and credit risk: ~$122B long-term debt, 3.67 debt-to-equity, and ~$260B in future data-center commitments could lead to downgrades, dilution, or higher interest costs.
• Backlog conversion may be slower than expected, validating the overcapacity thesis and pressuring the stock if AI demand softens.
• Intense competition from hyperscalers and cloud rivals could pressure OCI's pricing and long-run margins.

I lean bullish at $151.92 because the valuation has reset well below Oracle's own historical range while revenue growth is accelerating and the RPO backlog is enormous. The offset is real: negative FCF, heavy debt, and execution risk on an unprecedented AI capex build. This is a high-risk, high-reward bet on Oracle converting backlog into cash flow; if it does, the stock is likely meaningfully undervalued.

Calculated by applying a 26x forward P/E to consensus FY2027 EPS of $8.06, yielding $209.50. The 26x multiple is a deliberate discount to Oracle's 5-year average P/E of 34.4x to reflect the high debt load, negative FCF, and capex intensity, while still crediting the accelerating revenue growth and large RPO backlog.